According to the American Diabetes Association , studies comparing GLP-1 medications have demonstrated significant weight loss potential for both semaglutide and tirzepatide
GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
For federal employees and annuitants, this means youll see a wide range of cost and coverage options for weight-loss drugs from FEHB plans
For the latest on Phase 3 TRIUMPH trial progress, see our Retatrutide 2026 Phase 3 Update
Months 3-6: As weight loss slows and stabilizes, shedding gradually decreases
An empty stomach reduces competing absorption processes and keeps blood flow focused on the oral tissues
